Search

Author/Creator Massard, C.

2. 2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC). (September 2015)

Authors:
Chi, K.; Castellano, D.; De Bono, J.; Gravis, G.; Dirix, L.; Machiels, J.P.; Mita, A.; Mellado Gonzalez, B.; Massard, C.; Trandafir, L.; Dey, D.; Csonka, D.; Chakravartty, A.; Fizazi, K.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S493
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors. (September 2015)

Authors:
Italiano, A.; Keilhack, H.; Toulmonde, M.; Coindre, J.M.; Michot, J.M.; Massard, C.; Ottesen, L.; Reyderman, L.; Blakemore, S.J.; Kraljevic, S.; Thomson, B.; McDonald, A.; Ho, P.T.; Ribrag, V.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S54
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors. (September 2015)

Authors:
De Weger, V.; Varga, A.; De Jonge, M.; Langenberg, M.; Mergui-Roelvink, M.; Massard, C.; Van der Vlist, A.; Devriese, L.; Goodstal, S.; Zheng, W.; Tuffal, G.; Semiond, D.; Macé, S.; Watters, J.; Demers, B.; Schellens, J.; Deutsch, E.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S55
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 304 Vanucizumab reduces vessel permeability, perfusion and cellular density of tumor lesions in cancer patients as measured by DCE-MRI and DW-MRI. (September 2015)

Authors:
Nayak, T.; Massard, C.; Martinez Garcia, M.; Le Tourneau, C.; Boni, V.; Garralda, E.; Taus, A.; Albanell, J.; Lahr, A.; Krieter, O.; Hidalgo, M.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S55
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 349 Impact of the re-definition of dose-limiting toxicities (DLTs) according to recent recommendations on the DLT rate in phase 1 trials of molecularly targeted agents. (September 2015)

Authors:
Helissey, C.; Poterie, A.; Massard, C.; Hollebecque, A.; Paoletti, X.; Lanoy, E.; Soria, J.C.; Postel-Vinay, S.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S70
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 431 Biomarkers related to Vanucizumab single agent therapy in serial plasma, tumor tissue and skin wound-healing biopsies of patients with advanced solid tumors. (September 2015)

Authors:
Babitzki, G.; Hidalgo, M.; Massard, C.; Garcia, M. Martinez; Tourneau, C. Le; Boni, V.; Mestres, J. Albanell; Garcia, A. Taus; Alt, M.; Sablin, M.P.; Gerber, P.; Krieter, O.; Lahr, A.; Palme, S.; Rossomanno, S.; Harring, S. Vega; Wild, N.; Zajac, M.; Lechner, K.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S88
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 467 Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO-01. (September 2015)

Authors:
Haspinger, E.R.; Rosellini, S.; Ammari, S.; Dercle, L.; Bluthgen, M.V.; Besse, B.; Caramella, C.; Massard, C.; Lacroix, L.; Baere, T. De; Deschamps, F.; Michiels, S.; Soria, J.C.; Ferte, C.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S101
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗